CTOs on the Move


 
XIFIN, Inc. is an innovative software and services company dedicated to optimizing the economics of healthcare. The company`s cloud-based technology and business intelligence platform links healthcare stakeholders in the delivery and reimbursement of care, optimizing both business and patient outcomes and providing informed, streamlined diagnostic and business decision-making.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.xifin.com
  • 12225 El Camino Real
    San Diego, CA USA 92130
  • Phone: 858.793.5700

Executives

Name Title Contact Details
John Kelly
Chief Information Officer Profile

Similar Companies

Medical Resources

Medical Resources is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Protab Laboratories

Protab Laboratories is a Rancho Santa Margarita, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

St Cloud Hospital Recovery PLS

St Cloud Hospital Recovery PLS is a Saint Cloud, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lifesource Upper Midwest Organ

Lifesource Upper Midwest Organ is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Versartis

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.